14 September 2015

Ellex releases first case study results for 2RT at major tradeshow

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it released its first case study results from commercial users of its 2RT™ retinal rejuvenation laser.

In conjunction with Ellex’s commercial release of 2RT™ at the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Barcelona, Spain, 5-9 September 2015, Dr Christopher Kiss PhD (Austria) and Dr David Worsley MB, ChB, Dip Obs, FRANZCO (New Zealand) also released results of their clinical experience with 2RT™.

Dr Worsley stated with respect to a particular case (attached) “2RT™ Nano second laser has demonstrated an effective intervention for degeneration and improvement in macular function”.

Dr Kiss similarly concluded “For me this case [attached] represents 2RT™ providing a benefit in macular function and appearance in patients with drusen and functional defects. I will continue to consider 2RT™ for further intermediate AMD patients”.

Doctor’s Kiss and Worlsey are part of a growing cohort of doctors who have purchased a 2RT™ laser for use in their clinics. Along with the other early adopters Ellex calculates that, as of mid-August 2015, commercial 2RT™ procedures have carried out on approximately 1,000 patients. The positive case studies generated through these pioneering procedures will be an important marketing tool for Ellex to demonstrate the potential of the 2RT™ device to other clinicians.

Ellex CEO, Tom Spurling, stated “The long term LEAD clinical trial on 2RT™ being conducted in Australia is expected to ultimately provide quantative data on the efficacy of 2RT™. In the meantime our early adopters are providing important information about 2RT™’s clinical usage and potential.”


Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5293 | M +61 417 818 658

Maria Maieli, CFO & Company Secretary
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5200

Andrew Angus
Investor Relations
M +61 402 823 757